Related Experiment Video

Updated: Aug 18, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

16,090: the 2004 estimated U.S. mortality from ovarian cancer

M Steven Piver

    Gynecologic Oncology
    |March 26, 2005
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
    10:58

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

    Published on: July 18, 2016

    In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
    13:04

    In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

    Published on: October 14, 2015

    Related Experiment Videos

    Last Updated: Aug 18, 2026

    An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
    05:42

    An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

    Published on: January 26, 2024

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
    10:58

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

    Published on: July 18, 2016

    In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
    13:04

    In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

    Published on: October 14, 2015

    Related Concept Videos

    Oogenesis02:07

    Oogenesis

    In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...

    Articles linked to this work by shared authors, journal, and citation graph.

    The twenty-first century role of Piver-Rutledge type III radical hysterectomy and FIGO stage IA, IB1, and IB2 cervical cancer in the era of robotic surgery: a personal perspective.

    Journal of gynecologic oncology·2011

    21st century challenge of ovarian cancer in the elderly. A personal perspective.

    Oncology (Williston Park, N.Y.)·2009

    Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers.

    Cancer·2009

    Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.

    Human mutation·2007

    Screening for the BRCA1-ins6kbEx13 mutation: potential for misdiagnosis. Mutation in brief #964. Online.

    Human mutation·2007

    The role of hereditary nonpolyposis colorectal cancer in the management of familial ovarian cancer.

    Genetics in medicine : official journal of the American College of Medical Genetics·2006

    Planning and feasibility of phase III surgical trials in gynecologic oncology.

    Gynecologic oncology·2026

    Minimally invasive surgery without a uterine manipulator versus open radical hysterectomy for early-stage cervical cancer: A retrospective propensity-score-matched single-center cohort study.

    Gynecologic oncology·2026

    Mutated p53 results in altered type I interferon pathway expression and signaling in endometrial cancer.

    Gynecologic oncology·2026

    Molecular groups predict response to fertility-sparing treatment of endometrial carcinoma: a systematic review and metanalysis.

    Gynecologic oncology·2026

    Molecular characterization of NSMP endometrial cancer and its relevance for treatment.

    Gynecologic oncology·2026

    High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention.

    Gynecologic oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us